PSTX: Bathi resik saben saham (EPS TTM) Poseida

Poseida Therapeutics (PSTX) generates revenue by licensing its piggyBac platform to develop oncology drugs in collaboration with global partners. This 12-month net income per share chart shows that the metric has settled at -0.63. High R&D risks are mitigated by strategic alliances with pharma behemoths. Its status as a scientific elite in genetic engineering provides the company with an impeccable level of investor confidence.

PSTX (Poseida Therapeutics) riwayat Bathi resik saben siji saham sajrone rolas wulan pungkasan saka 04.07.2022 nganti 18.01.2025

Poseida Therapeutics - rincian analitis lan metrik utama (PSTX)

- rega saham lan prakiraan rega para ahli:

Kutipan saham Poseida Therapeutics, Inc.|PSTX - Konsensus nilai wajar

- informasi kapitalisasi pasar:

Kapitalisasi pasar Poseida Corp|PSTX - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Poseida Therapeutics|PSTX - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku poseida.com|PSTX - Aset Agregat Perusahaan

- data utang lan likuiditas:

- indikator pendapatan resik lan kelipatan nilai:

PSTX - Bathi perusahaan|Proyeksi bathi mangsa ngarep Poseida Therapeutics|PSTX - Kapitalisasi marang bathi|Prakiraan rega marang bathi Poseida|PSTX - Koefisien bali modal nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Poseida Therapeutics, Inc.|PSTX - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi resik saben saham (EPS TTM) Poseida Therapeutics|PSTX - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan poseida.com|PSTX - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Poseida Therapeutics

- data pendapatan lan penerimaan dodolan:

PSTX - Pendapatan dodolan perusahaan|Prakiraan volume dodolan poseida.com|PSTX - Multiplikator P/S|Rasio rega marang prakiraan pendapatan Poseida Therapeutics Inc

Analisis umum perusahaan:poseida.com (PSTX)

Poseida Therapeutics (PSTX) is developing innovative gene therapy methods in partnership with Roche. By analyzing the company's net income per share TTM, an investor can observe profitability trends over the year. This metric is calculated as the ratio of total net income to the number of common shares, excluding reporting time lags. The current value of -0.63 reflects the real-time efficiency of the capitalization of its developments. This indicator allows for an objective assessment of the business's financial stability.

Analisis perusahaan pesaing